GlassScriptPhysician profile
Samantha P Mitchell
NPI 1104656842
$433.74
in general payments reported to CMS, 2019-2025
15 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $68.72 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $44.31 | 2025 | Rexulti |
| Amgen INC. | $40.37 | 2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $32.86 | 2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $31.67 | 2025 | Airsupra |
| Lilly USA, LLC | $30.24 | 2025 | Zepbound, Mounjaro |
| Seqirus USA INC | $28.19 | 2025 | Flucelvax, Fluad |
| Sumitomo Pharma America, INC. | $25.69 | 2025 | Gemtesa |
| Vanda Pharmaceuticals INC. | $23.67 | 2025 | Fanapt, Hetlioz |
| Braeburn INC. | $19.21 | 2025 | Brixadi |
| Viiv Healthcare Company | $18.70 | 2025 | Apretude |
| Organon LLC | $18.59 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $17.87 | 2025 | |
| Alkermes, INC. | $17.27 | 2025 | Aristada, Lybalvi |
| Cranial Technologies, INC | $16.38 | 2025 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.